FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0104

Estimated average burden hours per response: 0.5

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Persor Horowitz Limited Partnershi VIII	' Requirin	of Event ng Statement Day/Year) 2020	3. Issuer Name and Ticker or Trading Symbol Tarsus Pharmaceuticals, Inc. [TARS]							
(Last) (First) (Middle)			4. Relationship of Reportsuer (Check all applicable)	()		5. If Amendment, Date of Original Filed (Month/Day/Year)				
5030 CAMPUS DRIVE, SUITE A			Director Officer (give	X	Other (er (specify		6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person		
(Street) NEWPORT BEACH CA 92660			title below)	below)			X			
(City) (State) (Zip)										
Table I - Non-Derivative Securities Beneficially Owned										
1. Title of Security (Instr. 4)			2. Amount of Securities Beneficially Owned (Ins 4)					4. Nature of Indirect Beneficial Ownership (Instr. 5)		
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)										
1. Title of Derivative Security (Instr. 4)	2. Date Exerc Expiration D (Month/Day/	ate	3. Title and Amount of Securit Underlying Derivative Security (Instr. 4)		ty Conver		sion C	5. Ownership Form:	6. Nature of Indirect Beneficial Ownership (Instr.	
	Date Exercisable	Expiration Date	Title		ount or nber of res	Price of Derivative Security		Direct (D) or Indirect (I) (Instr. 5)	5)	
Series A Preferred Stock	(1)	(1)	Common Stock	1,4	34,790	(1)		D		
Series B Preferred Stock	(2)	(2)	Common Stock	24	5,966	(2)		D		
Series C Preferred Stock	(3)	(3)	Common Stock	7	1,427	(3)		D		
Series A Preferred Stock	(1)	(1)	Common Stock	43	3,151	(1)		I	By the Adam S. Horowitz Revocable Trust ⁽⁴⁾	
Series B Preferred Stock	(2)	(2)	Common Stock	7	,396	(2)		I	By the Adam S. Horowitz Revocable Trust ⁽⁴⁾	

Explanation of Responses:

- 1. The Series A Preferred Stock shall automatically convert into shares of the Issuer's common stock, par value \$0.0001 per share (the "Common Stock"), on a one-for-one basis, immediately prior to the closing of the Issuer's initial public offering. The Series A Preferred Stock has no expiration date.
- 2. The Series B Preferred Stock shall automatically convert into shares of Common Stock, on a one-for-one basis, immediately prior to the closing of the Issuer's initial public offering. The Series B Preferred Stock has no expiration date.
- 3. The Series C Preferred Stock shall automatically convert into shares of Common Stock, on a one-for-one basis, immediately prior to the completion of the Issuer's initial public offering. The Series C Preferred Stock has no expiration date.
- 4. The shares are held by the Adam S. Horowitz Revocable Trust, of which Adam S. Horowitz is Trustee. Adam S. Horowitz is affiliated with Horowitz Limited Partnership VIII.

Remarks:

/s/ Jason Tester, as Chief
Financial Officer of
Horowitz Management,
Inc., the managing partner
of Horowitz Limited
Partnership VIII

10/15/2020

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.